Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cook Medical introduces Evolution for lead extraction
The company said that Evolution requires less surgical finesse and is more intuitive to use than laser-powered systems. It is also designed to negotiate chronic heavily fibrosed and
The company said that Evolution requires less surgical finesse and is more intuitive to use than laser-powered systems. It is also designed to negotiate chronic heavily fibrosed and
This operation, that will simplify the operational management, will be made in several steps and the process is expected to be completed substantially on December 31, 2007. Established
With more than 70 developing countries in the consortium, Cavidi said that the agreement is a significant step in making viral load monitoring more accessible to HIV-positive patients
In addition, it has secured a $1 million acquisition line of credit, to be used strictly for acquisition and asset purchases. The purchase price for the convertible notes
China-Biotics plans to begin construction in early December on the new manufacturing facility in Shanghai. Construction of the new plant is projected to cost $18 million, which will
Under the terms of the agreement, Starpharma will receive staged payments on successful completion of technical milestones within the collaborative project. The agreement also deals with commercialization rights
The patient, who was transplanted in November 2006, has finished the 12-month period of immunosuppression and follow-up, and undergone the last of the tests and observations required by
According to Conceptus, in addition to the enhanced ease-of-use, hysteroscopic visualization of the implant and placement markers was significantly improved. A new DryFlow Introducer, which alleviates distension fluid
This Phase III trial known as ZEST is designed to assess the efficacy of vandetanib versus erlotinib in overall survival and progression-free survival in over 1,150 patients with
Upon final approval, Teva’s product will be the AB-rated generic equivalent of GlaxoSmithKline’s Requip tablets, and will be indicated for the treatment of the signs and symptoms of